---
id: 161
title: Respiratory Syncytial Virus (RSV)
category: organisms
subcategory: respiratory_viruses
tags: [RSV, bronchiolitis, palivizumab, nirsevimab, ribavirin]
difficulty: medium
---

## Question

How is RSV managed in different populations? Use the **"Bronchiolitis in Infants = Supportive, Prevention: Nirsevimab (All Infants), Palivizumab (High-Risk)"** framework.

## Answer

### **Respiratory Syncytial Virus (RSV) Overview:**

**Transmission:** Respiratory droplets, fomites (survives hours on surfaces)

**Epidemiology:**
- **Seasonal:** Fall/winter in temperate climates
- **Most infants infected by age 2** (nearly universal exposure)
- **Reinfection common** (immunity incomplete)

### **Clinical Syndromes:**

**Bronchiolitis (Infants <2 Years):**

**Presentation:**
- **Prodrome:** URI symptoms (rhinorrhea, cough) × 2-3 days
- **Lower respiratory:** Wheezing, tachypnea, retractions, crackles
- **Feeding difficulty** (respiratory distress)
- **Apnea** (especially <3 months, premature infants)

**Severity Markers:**
- **Age <3 months, prematurity**
- **Hypoxia (O₂ sat <90%)**
- **Poor feeding, dehydration**
- **Apnea episodes**

**Adults (Especially Elderly/Immunocompromised):**
- **Upper respiratory infection** (rhinorrhea, cough, sore throat)
- **Pneumonia** (can be severe in elderly, COPD, transplant)
- **COPD exacerbation**

**High-Risk Groups:**
- **Premature infants** (<29 weeks gestation)
- **Chronic lung disease** (bronchopulmonary dysplasia)
- **Congenital heart disease** (hemodynamically significant)
- **Immunocompromised** (transplant, chemotherapy)
- **Elderly, COPD**

### **Diagnosis:**

**Clinical:** Often diagnosed clinically in bronchiolitis season

**Laboratory:**
- **Rapid antigen test** (nasopharyngeal swab) - moderate sensitivity
- **PCR** (respiratory viral panel) - gold standard, high sensitivity

### **Treatment:**

**Bronchiolitis (Infants) - Supportive Care:**

**Mainstay:**
- **Supplemental oxygen** (if hypoxic, O₂ sat <90%)
- **Hydration:** IV/NG fluids if poor PO intake
- **Nasal suctioning** (bulb suction, saline drops)
- **Monitor for apnea** (especially <3 months)

**NOT Recommended:**
- **Bronchodilators (albuterol):** No consistent benefit, NOT routine
- **Corticosteroids:** NOT effective
- **Antibiotics:** NOT indicated (viral) unless secondary bacterial infection suspected
- **Chest physiotherapy:** NOT effective

**Ribavirin:**
- **Rarely used** (limited efficacy, aerosolized, teratogenic risk to healthcare workers)
- **Consider only:** Severe disease in high-risk infants (immunocompromised, severe cardiopulmonary disease)

**Adults (High-Risk):**
- **Supportive care** (most cases)
- **Consider ribavirin** (aerosolized or IV) in severe cases (transplant, immunocompromised with pneumonia)

### **Prevention:**

**Nirsevimab (Beyfortus) - NEW 2024:**

**Indications:**
- **ALL infants <8 months** born during OR entering first RSV season
- **High-risk infants 8-19 months** entering second RSV season (chronic lung disease, severe immunocompromise, etc.)

**Dosing:**
- **<5 kg:** 50mg IM × 1
- **≥5 kg:** 100mg IM × 1

**Mechanism:** Long-acting monoclonal antibody (half-life ~5 months)

**Advantages:** Single dose, broader coverage than palivizumab

**Palivizumab (Synagis) - Traditional Prophylaxis:**

**Indications (If Nirsevimab Unavailable):**
- **Premature infants <29 weeks gestation** (first RSV season)
- **Chronic lung disease** (requiring medical support in past 6 months)
- **Hemodynamically significant congenital heart disease**
- **Severe immunocompromise**

**Dosing:**
- **15 mg/kg IM monthly** throughout RSV season (5 doses)

**RSV Vaccine (RSVPreF3, Abrysvo):**
- **Pregnant women:** 32-36 weeks gestation (protects newborn via maternal antibodies)
- **Adults ≥60 years:** Single dose (reduces severe RSV disease)

## Key Points

### **Supportive Care for Bronchiolitis:**
- **NO bronchodilators, steroids, antibiotics** (routine)
- **Oxygen, hydration, nasal suctioning**
- **Most recover without complications**

### **Nirsevimab = New Standard (2024):**
- **Single IM dose** (vs. 5 monthly doses of palivizumab)
- **ALL infants <8 months** during/entering first RSV season
- **Replaces palivizumab** as first-line prevention

### **Apnea Risk:**
- **<3 months, premature infants** at highest risk
- **Admission + monitoring** often needed

### **Ribavirin Rarely Used:**
- **Aerosolized** (teratogenic risk to staff)
- **Limited efficacy**
- **Consider only:** Severe disease in immunocompromised (transplant)

### **Maternal Vaccine:**
- **RSV vaccine in pregnancy** (32-36 weeks)
- **Protects newborn** via transplacental antibodies
- **Alternative to nirsevimab** (if mother vaccinated, infant may not need nirsevimab)

### **Clinical Pearls:**
- **Bronchiolitis:** Wheezing, tachypnea in infant (<2 years) during RSV season
- **Supportive care ONLY** (oxygen, hydration, suctioning)
- **NO albuterol, steroids, antibiotics** (routine)
- **Prevention:** Nirsevimab (ALL infants <8 months) OR maternal vaccine (32-36 weeks)
- **High-risk:** Premature, chronic lung disease, CHD, immunocompromised

## Sources

- [AAP: Bronchiolitis Guidelines 2024]
- [CDC: RSV Prevention (Nirsevimab) 2024]

## Media

N/A
